Drug intelligence / Profile preview

ugonin J

Development stage
Preclinical
Lead developer
Arjil Biotech
Modality
Small Molecules
Administration
Oral
01

Overview

Ugonin J is a bioactive prenylated flavonoid (specifically a cyclohexylmethyl flavonoid) isolated from the roots of the medicinal fern *Helminthostachys zeylanica*. It exhibits a wide range of pharmacological activities, including antioxidant, anti-inflammatory, anti-diabetic, anti-cancer, and antiviral properties. In preclinical studies, Ugonin J has been shown to suppress hepatocyte inflammation by enhancing glutathione peroxidase 2 (GPX2)-mediated redox regulation and reducing reactive oxygen species (ROS) levels. It also acts as an inhibitor of the SARS-CoV-2 3C-like protease (3CLpro), downregulates NANOG to suppress breast cancer stem cells, and inhibits prostate cancer progression by targeting the PI3K/Akt/NF-κB pathway and reducing ADAM9 expression. Additionally, it has demonstrated potential in ameliorating non-alcoholic fatty liver disease (NAFLD) and metabolic disorders via AMPK/Akt pathway regulation.

Other names
UJUgonin J
02

Targets

Sucrase-IsomaltaseMpro (3C-like proteinase of SARS-CoV-2)PTPN1 (Protein tyrosine phosphatase 1B)

Beyond the preview

Go deeper on ugonin J.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ugonin J.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call